In the three years since Cynthia Schwalm joined Ipsen’s North America operations, she’s handled the enviable challenge of managing aggressive growth and acquiring new assets for the pharmaceutical company…
With gene editing clinical trials starting in humans and drug pricing taking center stage in our industry, it’s important to remember our ethics. For most companies, an ethical business means playing by the rules, working honestly…
While finding and applying for jobs has become easier with the internet, the fundamentals of the process are the same. Writing skills, especially in the age of emails, are still extremely important. Whether your cover letter is being…
The patent fight over the gene-editing technique CRISPR has a winner – the Broad Institute of Cambridge, MA. The battle began when the University of California, Berkeley challenged a dozen patents held by the Broad Institute…
Husband-and-wife team Mark Zuckerberg and Priscilla Chan have given around $50M to fund 47 “CZ Biohub” investigators across U.S. academia. The couple pledged to invest around $3B over the next 10 years…
After a slow year for new drug approvals with the FDA only approving 22 meds in 2016, we are looking forward to how drugmakers do in 2017. No matter how many new drugs are approved this year, there are sure to…
The New York Times recently published a list of the 200 highest paid chief executive officers in the United States as researched and reported by Equilar. Check out where the top five biopharma CEOs ranked on that list…
When: March 7, 2017
Where: Philadelphia, PA
Life Sciences Collaborative presents “Why Invest in Philadelphia Now? – Converting Risk Capital to Success Stories”…
2016’s Fierce 15 are redefining what it means to be a medical device. If they’re not making big bets on new technologies, they’re reimagining existing ones. From video-game based therapies and liquid…
FDA medical officers – including those involved with product review and post-market safety monitoring across CDER, CBER and CDRH – will be exempt from the federal hiring freeze, according to an HHS memo. The full list of exempt…
At the very core of Ashton Tweed’s talent-acquisition and talent-placement business is a robust professional force of highly experienced life sciences industry experts. These uniquely talented professionals are deployed throughout Ashton Tweed’s diverse range of service offerings to solve our clients’ human capital and management needs.
